May 2019 TBC

Boston, USA

LinkedIn logo for website footerstwitter


TxCell is a French biotechnology company that develops cellular immunotherapies based on regulatory T lymphocytes (Tregs) for the treatment of severe inflammatory and autoimmune diseases with high unmet medical needs. More precisely, TxCell develops engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells). TxCell aims at shortly bringing this innovation for the first time to human testing, with a first IND filing (or equivalent) by end 2018.